Sanofi Says Pfizer’s PCSK9 Phase III Plan Will Boost The New Drug Class
This article was originally published in The Pink Sheet Daily
Sanofi CEO Christopher Viehbacher seemed unperturbed by Pfizer’s ambitious PCSK9 Phase III development program, saying it will increase interest in the new drug class.
You may also be interested in...
Sanofi CEO Chris Viehbacher showed clear signs of disappointment during the company’s earnings call, admitting emerging markets underperformed, and revealing a debacle in Brazil that appears to be channel stuffing.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.